YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue ...

HONG KONG, Mar 11, 2026 - (ACN Newswire) - March 9, 2025, Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY' (etrasimod arginine tablets) in Mainland China, highlighted by the ...

YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 - - Company earned $35.6 million in total revenue ...